Current management of hereditary angioedema with normal C1-inhibitor (nC1-HAE) in the United States: Results from a nationwide survey of HAE-treating physicians

Riedl MA1, Danese M2, Danese S2, Ulloa J2, and Maetzel A3

1Division of Rheumatology, Allergy and Immunology, University of California, CA, USA; 2Outcomes Insights Inc, Thousand Oaks, CA, USA; 3KalVista Pharmaceuticals, Inc. Cambridge, MA, USA

• Robust study data are lacking on the effective management of patients with nC1-HAE
• Patients are currently managed and treated with medications studied in patients with HAE types I & II

Background

- Robust study data are lacking on the effective management of patients with nC1-HAE
- Patients are currently managed and treated with medications studied in patients with HAE types I & II

Objectives

- Describe patterns of acute attacks in patients with nC1-HAE
- Explore current treatment patterns & unmet needs for nC1-HAE

Methodology

- 10-minute online survey
- IQVIA Xponent Prescriber Data
  - Sample: 974 prescriber records with 11,924 prescriptions, from May 2019 to April 2020
  - Market basket: Berinert, Cinryze, Ruconest, Haegarda, Firazyr, Kalbitor, Takhzyro
- Physicians were combined with physician assistant and/or their nurse practitioner, leaving 931 providers

Survey Screening criteria

- Board certified
- In practice <35 years
- Personally treated ≥5 HAE patients in the past 12 months
- Treated ≥1 patient with nC1-HAE in the past 12 months

IRB waiver

- IRB waiver granted in accordance with 45 CFR 46.104(d)(2)
- Date: June 8, 2020 (Advarra)

Conclusions

- Specialist practices managing HAE commonly evaluate and treat patients with nC1-HAE
- Dedicated condition-specific diagnostic tests and robust study data on the treatment of nC1-HAE are lacking. Future research on HAE diagnosis and treatment should include patients with nC1-HAE to improve care for this population